Show simple item record

dc.contributor.advisorMudrack, Kristen
dc.contributor.authorGeren, Kellee
dc.contributor.authorLamb, Andi
dc.date.accessioned2019-04-24T12:31:42Z
dc.date.available2019-04-24T12:31:42Z
dc.date.issued2019-04
dc.identifier.urihttp://hdl.handle.net/11558/4269
dc.description.abstractPseudomonas aeruginosa is a gram-negative bacterium that is difficult to treat. Cystic Fibrosis patients are likely to be affected by Pseudomonas aeruginosa, forcing patients to be prescribed antibiotics for an extended period of time. Antibiotic resistance develops quickly for antibiotics due to overuse and overexposure, therefore, new treatments that are effective and inexpensive to create are needed. In collaboration with the distributed drug discovery (D3) program started by IUPUI, solid phase synthesis of unnatural dipeptides was utilized to make six small molecule antibiotics that have potential bioactivity against P. aeruginosa. A microbiology assay was used to determine the interaction of the dipeptides with P. aeruginosa. The six novel dipeptides were tested against current antibiotic therapies to determine their effectiveness.en_US
dc.language.isoen_USen_US
dc.subjectPseudomonas aeruginosaen_US
dc.subjectDipeptidesen_US
dc.subjectAntibioticsen_US
dc.subjectCystic Fibrosisen_US
dc.subjectRISE Above Research Conference
dc.titleUnnatural Dipeptide Synthesis with Bioactivity Against P. aeruginosaen_US
dc.typeWorking Paperen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record


Milligan

© Milligan University. All Rights Reserved.